Cargando…
Medikamentöse Therapie des inoperablen Melanoms
Among established therapies for inoperable melanoma are immune checkpoint inhibition with cytotoxic T‑lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and lymphocyte activating gene 3 (LAG-3) inhibitors and, in the presence of a BRAF V600 mutation, targeted therapy w...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186319/ http://dx.doi.org/10.1007/s00761-023-01347-4 |
_version_ | 1785042534213353472 |
---|---|
author | Lodde, Georg Leven, Anna-Sophia Schadendorf, Dirk Gutzmer, Ralf |
author_facet | Lodde, Georg Leven, Anna-Sophia Schadendorf, Dirk Gutzmer, Ralf |
author_sort | Lodde, Georg |
collection | PubMed |
description | Among established therapies for inoperable melanoma are immune checkpoint inhibition with cytotoxic T‑lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and lymphocyte activating gene 3 (LAG-3) inhibitors and, in the presence of a BRAF V600 mutation, targeted therapy with BRAF/MEK inhibition. These systemic treatments have led to a significant improvement in the clinical outcome of metastatic melanoma patients. However, metastatic melanoma remains a therapeutic challenge, especially in cases of disease progression under systemic therapy. In this review, the established systemic treatments, e.g., immune checkpoint inhibition, targeted therapy, and local treatment options are presented. New therapy strategies such as sequence therapy and combination therapy for BRAF-mutated melanoma as well as new drugs in clinical studies and the increasingly personalized melanoma therapy are introduced. |
format | Online Article Text |
id | pubmed-10186319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-101863192023-05-17 Medikamentöse Therapie des inoperablen Melanoms Lodde, Georg Leven, Anna-Sophia Schadendorf, Dirk Gutzmer, Ralf Onkologie Leitthema Among established therapies for inoperable melanoma are immune checkpoint inhibition with cytotoxic T‑lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and lymphocyte activating gene 3 (LAG-3) inhibitors and, in the presence of a BRAF V600 mutation, targeted therapy with BRAF/MEK inhibition. These systemic treatments have led to a significant improvement in the clinical outcome of metastatic melanoma patients. However, metastatic melanoma remains a therapeutic challenge, especially in cases of disease progression under systemic therapy. In this review, the established systemic treatments, e.g., immune checkpoint inhibition, targeted therapy, and local treatment options are presented. New therapy strategies such as sequence therapy and combination therapy for BRAF-mutated melanoma as well as new drugs in clinical studies and the increasingly personalized melanoma therapy are introduced. Springer Medizin 2023-05-16 /pmc/articles/PMC10186319/ http://dx.doi.org/10.1007/s00761-023-01347-4 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Leitthema Lodde, Georg Leven, Anna-Sophia Schadendorf, Dirk Gutzmer, Ralf Medikamentöse Therapie des inoperablen Melanoms |
title | Medikamentöse Therapie des inoperablen Melanoms |
title_full | Medikamentöse Therapie des inoperablen Melanoms |
title_fullStr | Medikamentöse Therapie des inoperablen Melanoms |
title_full_unstemmed | Medikamentöse Therapie des inoperablen Melanoms |
title_short | Medikamentöse Therapie des inoperablen Melanoms |
title_sort | medikamentöse therapie des inoperablen melanoms |
topic | Leitthema |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186319/ http://dx.doi.org/10.1007/s00761-023-01347-4 |
work_keys_str_mv | AT loddegeorg medikamentosetherapiedesinoperablenmelanoms AT levenannasophia medikamentosetherapiedesinoperablenmelanoms AT schadendorfdirk medikamentosetherapiedesinoperablenmelanoms AT gutzmerralf medikamentosetherapiedesinoperablenmelanoms |